Immunic, Inc. (IMUX) — Analyst outlook / Analyst consensus target is. Based on 12 analyst ratings, the consensus is bullish — 11 Buy, 1 Hold.
The consensus price target is $5.00, representing an upside of 350.5% from the current price $1.11.
Analysts estimate Earnings Per Share (EPS) of $-0.96 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.00 vs est $-0.96 (missed -4.3%). 2025: actual $-0.62 vs est $-0.63 (beat +1.8%). Analyst accuracy: 97%.
IMUX Stock — 12-Month Price Forecast
$5.00
▲ +350.45% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Immunic, Inc., the price target is $5.00.
The average price target represents a +350.45% change from the last price of $1.11.
IMUX Analyst Ratings
Buy
Based on 12 analysts giving stock ratings to Immunic, Inc. in the past 3 months
EPS Estimates — IMUX
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.00
vs Est –$0.96
▼ 4.2% off
2025
Actual –$0.62
vs Est –$0.63
▲ 1.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — IMUX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
